Paper Details

  1. Home
  2. Paper Details

Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis.

Author: BlairHannah A, KangConnie

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Ofatumumab, a self-administered drug for relapsing multiple sclerosis (MS), was more effective than teriflunomide in reducing relapse rates and MRI-detected lesions. The drug had a manageable tolerability profile with common side effects like infections and injection-related reactions.
Paper Details　
Original Abstract of the Article :
Ofatumumab (Kesimpta<sup>&#174;</sup>) is a fully human anti-CD20 monoclonal antibody that can be self-administered by patients and is approved in several countries worldwide for the treatment of relapsing forms of multiple sclerosis (MS). In two identical phase III trials in adults with relapsing f...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8748350/

データ提供：米国国立医学図書館（NLM）

Ofatumumab: A Novel Treatment for Relapsing Forms of Multiple Sclerosis

Ofatumumab (Kesimpta®) is a fully human anti-CD20 monoclonal antibody currently in use for the treatment of relapsing forms of multiple sclerosis (MS). This research focuses on the efficacy and safety of ofatumumab in treating MS. The study employed a double-blind, randomized controlled trial design, comparing ofatumumab to teriflunomide, a commonly used oral medication. Researchers discovered that ofatumumab was significantly more effective in reducing the annualized relapse rate, MRI-detected lesion activity, and disability progression. Notably, ofatumumab demonstrated a manageable tolerability profile, with the most common side effects being nasopharyngitis, headaches, and upper respiratory tract infections.

Promising Results for a Challenging Disease

The findings suggest that ofatumumab offers a valuable treatment option for individuals with relapsing forms of MS. The drug's ability to reduce relapses and disability progression, coupled with a manageable side effect profile, makes it a potentially transformative treatment for this complex neurological condition. The results from this study contribute significantly to the ongoing search for effective and safe therapies for MS.

Navigating the Desert of MS Research

Imagine the sands of the desert, shifting and ever-changing. This is how I envision MS research. Every new finding, like an oasis, offers hope and relief. This study demonstrates the power of ofatumumab in combating MS symptoms, a beacon of light in the relentless desert of this disease.

Dr. Camel's Conclusion

Ofatumumab proves to be a promising treatment option for individuals with relapsing forms of MS, offering potential for reduced relapses, disability progression, and manageable side effects. This research highlights the ongoing efforts to combat this complex neurological condition and provides hope for a future where MS is better understood and effectively managed.

Date :
  1. Date Completed 2022-02-18
  2. Date Revised 2022-02-18
Further Info :

Pubmed ID

34897575

DOI: Digital Object Identifier

PMC8748350

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.